INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $434,000 | -27.5% | 16,916 | -27.5% | 0.00% | 0.0% |
| Q2 2020 | $599,000 | +9.1% | 23,328 | -34.7% | 0.00% | 0.0% |
| Q1 2020 | $549,000 | -46.6% | 35,728 | +19.1% | 0.00% | 0.0% |
| Q4 2019 | $1,029,000 | +433.2% | 30,000 | +101.3% | 0.00% | – |
| Q2 2019 | $193,000 | +11.6% | 14,900 | +4.9% | 0.00% | – |
| Q1 2019 | $173,000 | +6.8% | 14,200 | 0.0% | 0.00% | – |
| Q4 2018 | $162,000 | -64.6% | 14,200 | -32.7% | 0.00% | -100.0% |
| Q3 2018 | $458,000 | -31.2% | 21,100 | -44.0% | 0.00% | 0.0% |
| Q2 2018 | $666,000 | -35.6% | 37,700 | -23.2% | 0.00% | -50.0% |
| Q1 2018 | $1,034,000 | +353.5% | 49,100 | +250.7% | 0.00% | – |
| Q1 2017 | $228,000 | -1.3% | 14,000 | -8.5% | 0.00% | – |
| Q4 2016 | $231,000 | +6.9% | 15,300 | +7.7% | 0.00% | – |
| Q3 2016 | $216,000 | – | 14,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |